Brief: Acadia Pharmaceuticals Announces FDA Approval Of DAYBUE STIX For Oral Solution, A New Powder Formulation Of Trofinetide For The Treatment Of Rett Syndrome
12/12/2025 13:02
Dec 12 (Reuters) - ACADIA Pharmaceuticals Inc ACAD.O: ACADIA PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF DAYBUE® STIX (TROFINETIDE) FOR ORAL SOLUTION, A NEW POWDER FORMULATION OF TROFINETIDE FOR THE TREATMENT OF RETT SYNDROME Source text: ID:nBw1JprCDa Further company coverage: ACAD.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry